New drug shows promise for Hard-to-Treat blood cancer
NCT ID NCT06479954
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This study looks at the long-term safety and effectiveness of the drug elranatamab in people with multiple myeloma that has come back or stopped responding to other treatments. Researchers will track side effects like cytokine release syndrome and nerve problems, as well as how well the drug controls the cancer. The study involves one participant who has already received at least one dose of elranatamab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.